Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOICES
2022-500410-26-01Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of dirocaftor, Posenacaftor and nesolicaftor in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Mean percent predicted FEV1 (ppFEV1) after treatment. Started Apr 2024; status: completed.
02
Drugs
dirocaftorPosenacaftornesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2022-500410-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500410-26-01.